CD8A and neoplasm: However, with the current study, we have shown that the specific delivery of IL-2 with the NKG2D-Fc system led to both the expansion of tumor antigen-specific CD8+ T cells at the tumor loci and an improved therapeutic anti-tumor effect generated by the therapeutic DNA vaccine.